A new study suggests that two widely used Type 2 diabetes medications—GLP-1 receptor agonists and SGLT2 inhibitors—may help reduce the risk of Alzheimer’s disease and related dementias. Researchers analyzed Medicare data and found that patients taking these drugs had significantly lower rates of cognitive decline compared to those using other glucose-lowering medications.
MillaF/Shutterstock Injectable medications originally developed for the treatment of diabetes are also effective for weight loss, and have surged in popularity for this purpose around the world. In Australia, Ozempic is approved for the treatment of type 2 diabetes, while Wegovy is approved for weight management. Both are formulations of the drug semaglutide, which mimics … Read more
We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Felix. In this article, we will summarize the bulls’ thesis on NVO. Novo Nordisk A/S (NVO)’s share was trading at $64.49 as of April 15th. NVO’s trailing and forward P/E were 18.76 and 15.41 respectively according to Yahoo Finance. A scientist in a … Read more
Wellness startups are launching products that target the natural growth of GLP-1, the hormone that medicines like Ozempic and Mounjaro mimic. Experts warn that the traditional wellness industry must adapt to remain relevant in the market